SHENZHEN, China, July 3, 2012 \/PRNewswire-Asia\/-- A study conducted by Beike Biotechnology Company (http:\/\/www.beikebiotech.com<\/a>) in conjunction with physicians and researchers at two Chinese hospitals, documents the effectiveness of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC). The study, which was published in the April 2012 issue of the Stem Cell Discovery, was the first of its kind. Researchers noted that additional clinical trials would be required before stem cells can become an accepted therapy for liver cirrhosis. <\/p>\n Prof. Jin-hui Yang, Director of the Department of Hepatology in the 2nd Affiliated Hospital of Kunming Medical College stated, \"Given the severity of liver cirrhosis and its related conditions, and the limited number of options available to treat those who suffer from it, this finding represents an important, potentially significant breakthrough.\" <\/p>\n PBC is a chronic, progressive liver disease that leads eventually to fibrosis and cirrhosis of the liver. It affects 1 in 1,000 women over the age of 40.Approximately one-third of those who suffer from PBC and its related conditions do not respond well to Ursodeoxycholic acid (UDCA) treatment, which is the only currently FDA-approved standard medical treatment for the condition. Many of those patients ultimately require liver transplantation. <\/p>\n Beike Chairman, Dr. Sean Hu, commented, \"With a growing body of research that demonstrates the effectiveness of cord blood-derived stem cell therapies in treating a broad range of chronic conditions, this latest study is a milestone in the continuing effort to gain broad acceptance and recognition of regenerative medicine as a mainstream treatment option.We look forward to conducting more comprehensive clinical trials to attempt to validate the positive outcomes we have already observed.\" <\/p>\n The case study reported in the Stem Cell Discovery involved a 58 year old woman suffering from PBC who developed an incarcerated hernia and uncontrolled hydrothorax after undergoing UDCA treatment.One week after completing two stem cell transplantations with no observed adverse effects, the patient showed improvement in both liver function and in her general condition. She was released from the hospital but continued to receive twice-daily UDCA treatments. Six months after her discharge, doctors observed continued improvements in her liver function and overall condition. <\/p>\n To review the full text of the published study, please visit: http:\/\/www.scirp.org\/journal\/PaperInformation.aspx?paperID=18710<\/a>. Study authors included physicians and researchers from the 2nd Affiliated Hospital of Kunming Medical College, Beike Biotechnology Company, and the Yunnan Provincial 1st People's Hospital in Kunming, China. <\/p>\n About Beike Biotechnology Company <\/p>\n Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on the production of adult stem cells for use in medical therapies. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow. <\/p>\n For any questions regarding this release, please call: <\/p>\n Contact Person: T. Gutmann Phone Number: +86-532-6677-6659 <\/p>\n<\/p>\n See original here: <\/p>\n Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" SHENZHEN, China, July 3, 2012 \/PRNewswire-Asia\/-- A study conducted by Beike Biotechnology Company (http:\/\/www.beikebiotech.com<\/a>) in conjunction with physicians and researchers at two Chinese hospitals, documents the effectiveness of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC). The study, which was published in the April 2012 issue of the Stem Cell Discovery, was the first of its kind Continue reading